Literature DB >> 35536437

Regulation of osteoclast-mediated bone resorption by microRNA.

Ling Ji1, Xinyi Li1, Shushu He2, Song Chen3.   

Abstract

Osteoclast-mediated bone resorption is responsible for bone metabolic diseases, negatively impacting people's health and life. It has been demonstrated that microRNA influences the differentiation of osteoclasts by regulating the signaling pathways during osteoclast-mediated bone resorption. So far, the involved mechanisms have not been fully elucidated. This review introduced the pathways involved in osteoclastogenesis and summarized the related microRNAs binding to their specific targets to mediate the downstream pathways in osteoclast-mediated bone resorption. We also discuss the clinical potential of targeting microRNAs to treat osteoclast-mediated bone resorption as well as the challenges of avoiding potential side effects and producing efficient delivery methods.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Bone resorption; MicroRNA; Osteoclast; Signaling pathways

Mesh:

Substances:

Year:  2022        PMID: 35536437     DOI: 10.1007/s00018-022-04298-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  199 in total

Review 1.  New regulation mechanisms of osteoclast differentiation.

Authors:  Tomoki Nakashima; Hiroshi Takayanagi
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

Review 2.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

Review 3.  New insights into osteoclastogenic signaling mechanisms.

Authors:  Tomoki Nakashima; Mikihito Hayashi; Hiroshi Takayanagi
Journal:  Trends Endocrinol Metab       Date:  2012-06-15       Impact factor: 12.015

Review 4.  An overview and management of osteoporosis.

Authors:  Tümay Sözen; Lale Özışık; Nursel Çalık Başaran
Journal:  Eur J Rheumatol       Date:  2016-12-30

Review 5.  Advances in the regulation of osteoclasts and osteoclast functions.

Authors:  B F Boyce
Journal:  J Dent Res       Date:  2013-08-01       Impact factor: 6.116

Review 6.  Osteoclastic microRNAs and their translational potential in skeletal diseases.

Authors:  Kazuki Inoue; Shinichi Nakano; Baohong Zhao
Journal:  Semin Immunopathol       Date:  2019-10-07       Impact factor: 9.623

Review 7.  Genetic and transcriptional control of bone formation.

Authors:  Amjad Javed; Haiyan Chen; Farah Y Ghori
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2010-08       Impact factor: 2.802

Review 8.  The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?

Authors:  M A Karsdal; A C Bay-Jensen; R J Lories; S Abramson; T Spector; P Pastoureau; C Christiansen; M Attur; K Henriksen; S R Goldring; V Kraus
Journal:  Ann Rheum Dis       Date:  2013-11-27       Impact factor: 19.103

Review 9.  Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption.

Authors:  Brendan F Boyce; Jinbo Li; Lianping Xing; Zhenqiang Yao
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

Review 10.  Roles of MicroRNAs in Bone Destruction of Rheumatoid Arthritis.

Authors:  Hanxiao Zhao; Aiping Lu; Xiaojuan He
Journal:  Front Cell Dev Biol       Date:  2020-11-19
View more
  2 in total

1.  KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK.

Authors:  Laura Salvadori; Maria Laura Belladonna; Beatrice Castiglioni; Martina Paiella; Eleonora Panfili; Tommaso Manenti; Catia Ercolani; Luca Cornioli; Sara Chiappalupi; Giulia Gentili; Massimiliano Leigheb; Guglielmo Sorci; Michela Bosetti; Nicoletta Filigheddu; Francesca Riuzzi
Journal:  Nutrients       Date:  2022-07-25       Impact factor: 6.706

Review 2.  The monocyte-to-osteoclast transition in rheumatoid arthritis: Recent findings.

Authors:  Naoki Iwamoto; Atsushi Kawakami
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.